Indian drug giant Cipla slashes cancer drug prices
Indian drugs giant Cipla said Friday it has slashed by up to 76 percent prices of generic medicines used to treat brain, lung and kidney cancer in what the company called a "humanitarian move".
To put things into a perspective: the real costs of drugs comes from research and clinical trials phases. When patent protection expires and drugs reach generic status, the business becomes not much different from selling soda or chewing gum: the only costs are manufacturing (usually cheap) and marketing. In this case the line between “humanitarian move” and marketing is a difficult one to draw.